SAN DIEGO–(BUSINESS WIRE)–Epirium Bio Inc. (Epirium), a clinical-stage biopharmaceutical company advancing medicines for neuromuscular and fibrotic diseases, announced today that new clinical and translational data for MF-300 will be presented in two oral sessions at the Intrinsic Capacity, Frailty and Sarcopenia Research Conference (ICFSR) 2026, taking place March 10-12 in Washington, DC. MF-300 is an investigational, first-in-class, orally administered, 15-hydroxyprostaglandin dehydrogenase
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
